| Literature DB >> 29497311 |
Ling Min1, Xiyan Mu1, An Tong1, Yanping Qian1, Chen Ling1, Tao Yi1, Xia Zhao1.
Abstract
OBJECTIVES: This work aims to explore whether HOX transcript antisense intergenic RNA (HOTAIR) polymorphisms are associated with cancer susceptibility.Entities:
Keywords: HOTAIR; cancer; meta-analysis; polymorphism; susceptibility
Year: 2018 PMID: 29497311 PMCID: PMC5818844 DOI: 10.2147/OTT.S151454
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1The flow diagram of study selection.
Abbreviation: HOTAIR, HOX transcript antisense intergenic RNA.
Characteristics of included studies
| Reference | Year | Ethnicity | SNPs | Cancer type | Source of control | Genotyping method | Adjusted factors | Study quality |
|---|---|---|---|---|---|---|---|---|
| Bayram et al | 2016 | Turkish | rs12826786 (C/T) | Breast cancer | Hospital | TaqMan | Age | 7 |
| Bayram et al | 2015 | Turkish | rs920778 (T/C) | Gastric cancer | Hospital | TaqMan | Age, gender, smoking, drinking | 7 |
| Bayram et al | 2015 | Turkish | rs920778 (T/C) | Breast cancer | Hospital | TaqMan | Age, gender | 7 |
| Du et al | 2015 | Chinese | rs4759314 (A/G) | Gastric cancer | Hospital | TaqMan | Age, gender | 8 |
| Guo et al | 2015 | Chinese | rs4759314 (A/G) | Gastric cancer | Hospital | PCR-RFLP | Age, gender, smoking status | 7 |
| Jin et al | 2017 | Chinese | rs7958904 (G/C) | Cervical cancer | Hospital | TaqMan | Not known | 7 |
| Pan et al | 2016 | Chinese | rs4759314 (A/G) | Gastric cancer | Population | PCR-RFLP | Age, gender | 7 |
| Qiu et al | 2016 | Chinese | rs920778 (T/C) | Ovarian cancer | Not known | TaqMan | Age, parity, smoking, menopausal status | 6 |
| Qiu et al | 2016 | Chinese | rs920778 (C/T) | Cervical cancer | Not known | TaqMan | Age | 6 |
| Taheri et al | 2017 | Iranian | rs4759314 (A/G) | Prostate cancer | Hospital | ARMS-PCR | Age, BMI, smoking | 7 |
| Ulger et al | 2017 | Turkish | rs12826786 (C/T) | Gastric cancer | Hospital | TaqMan | Age, gender, smoking, drinking | 7 |
| Wu et al | 2016 | Chinese | rs7958904 (G/C) | Ovarian cancer | Not known | RT-PCR | Age, drinking, BMI | 6 |
| Xavier-Magalhães et al | 2017 | Portuguese | rs12826786 (C/T) | Glioma | Population | PCR-RFLP | Age, gender | 8 |
| Xue et al | 2015 | Chinese | rs7958904 (G/C) | Colorectal cancer | Hospital | TaqMan | Age, gender, drinking | 7 |
| Yan et al | 2015 | Chinese | rs4759314 (A/G) | Breast cancer | Population | PCR-RFLP | Age, menopause age, menstrual history, No of pregnancy, No of abortion, breast feeding | 8 |
| Zhang et al | 2014 | Chinese | rs4759314 (A/G) | Esophageal cancer | Hospital | RT-PCR | Age, gender | 8 |
| Zhu et al | 2016 | Chinese | rs4759314 (A/G) | Thyroid cancer | Not known | PCR-RFLP | Age, gender | 6 |
| Zhu et al | 2016 | Chinese | rs7958904 (G/C) | Colorectal cancer | Hospital | TaqMan | Age, gender, smoking, drinking, meal regularity, grain intake | 7 |
Abbreviations: ARMS-PCR, amplification-refractory mutation system-polymerase chain reaction; BMI, body mass index; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; RT-PCR, real-time polymerase chain reaction; SNP, single-nucleotide polymorphism.
Genotype distributions of included studies
| SNP | References | Year | Cancer type | Case number | Control number | Case
| Control
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rec | Hetero | Dom | Rec | Hetero | Dom | ||||||
| rs7958904 (G/C) | Jin et al | 2017 | Cervical caner | 1,153 | 1,292 | 86 | 427 | 640 | 63 | 494 | 735 |
| Wu et al | 2016 | Ovarian cancer | 1,000 | 1,000 | 51 | 355 | 594 | 87 | 380 | 533 | |
| Xue et al | 2015 | Colorectal cancer | 1,145 | 1,201 | 74 | 399 | 672 | 99 | 456 | 646 | |
| Zhu et al | 2016 | Colorectal cancer | 394 | 394 | 38 | 141 | 215 | 52 | 161 | 181 | |
| rs4759314 (A/G) | Du et al | 2015 | Gastric cancer | 1,275 | 1,644 | 6 | 186 | 1,083 | 8 | 172 | 1,464 |
| Guo et al | 2015 | Gastric cancer | 515 | 654 | 1 | 53 | 461 | 1 | 64 | 589 | |
| Jin et al | 2017 | Cervical cancer | 1,174 | 1,304 | 4 | 158 | 1,012 | 2 | 140 | 1,162 | |
| Pan et al | 2016 | Gastric cancer | 500 | 1,000 | 1 | 48 | 451 | 3 | 83 | 914 | |
| Taheri et al | 2017 | Prostate cancer | 125 | 250 | 7 | 32 | 86 | 6 | 81 | 163 | |
| Wu et al | 2016 | Ovarian cancer | 1,000 | 1,000 | 41 | 140 | 819 | 23 | 125 | 852 | |
| Xue et al | 2015 | Colorectal cancer | 1,147 | 1,203 | 1 | 135 | 1,011 | 9 | 157 | 1,037 | |
| Yan et al | 2015 | Breast cancer | 502 | 504 | 1 | 50 | 451 | 2 | 54 | 448 | |
| Zhang et al | 2014 | Esophageal cancer | 1,000 | 1,000 | 2 | 81 | 917 | 1 | 89 | 910 | |
| Zhu et al | 2016 | Thyroid cancer | 600 | 600 | 2 | 58 | 540 | 2 | 45 | 553 | |
| rs874945 (G/A) | Jin et al | 2017 | Cervical cancer | 1,171 | 1,289 | 43 | 383 | 745 | 43 | 394 | 852 |
| Wu et al | 2016 | Ovarian cancer | 1,000 | 1,000 | 52 | 283 | 665 | 44 | 279 | 677 | |
| Xue et al | 2015 | Colorectal cancer | 1,147 | 1,202 | 40 | 356 | 751 | 39 | 346 | 817 | |
| rs12826786 (C/T) | Bayram et al | 2016 | Breast cancer | 123 | 122 | 30 | 51 | 42 | 14 | 64 | 44 |
| Guo et al | 2015 | Gastric cancer | 515 | 654 | 30 | 200 | 285 | 19 | 232 | 403 | |
| Taheri et al | 2017 | Prostate cancer | 128 | 250 | 32 | 70 | 26 | 42 | 125 | 83 | |
| Ulger et al | 2017 | Gastric cancer | 105 | 207 | 20 | 47 | 38 | 35 | 99 | 73 | |
| Xavier-Magalhães et al | 2017 | Glioma | 177 | 199 | 16 | 77 | 84 | 21 | 84 | 94 | |
| rs1899663 (G/T) | Pan et al | 2016 | Gastric cancer | 490 | 1,020 | 6 | 118 | 366 | 13 | 255 | 752 |
| Taheri et al | 2017 | Prostate cancer | 127 | 250 | 22 | 70 | 35 | 40 | 133 | 77 | |
| Yan et al | 2015 | Breast cancer | 502 | 361 | 14 | 149 | 339 | 20 | 158 | 326 | |
| Zhang et al | 2014 | Esophageal cancer | 1,000 | 1,000 | 19 | 256 | 725 | 26 | 250 | 724 | |
| Zhu et al | 2016 | Thyroid cancer | 580 | 600 | 7 | 151 | 422 | 12 | 175 | 413 | |
| rs920778 (C/T) | Bayram et al | 2015 | Gastric cancer | 104 | 209 | 32 | 52 | 20 | 66 | 105 | 38 |
| Bayram et al | 2015 | Breast cancer | 123 | 122 | 40 | 52 | 31 | 41 | 66 | 15 | |
| Pan et al | 2016 | Gastric cancer | 800 | 1,600 | 59 | 321 | 420 | 45 | 575 | 980 | |
| Qiu et al | 2016 | Ovarian cancer | 329 | 680 | 25 | 69 | 235 | 22 | 78 | 580 | |
| Qiu et al | 2016 | Cervical cancer | 215 | 430 | 47 | 78 | 90 | 54 | 150 | 226 | |
| Xavier-Magalhães et al | 2017 | Glioma | 177 | 199 | 82 | 71 | 24 | 90 | 84 | 25 | |
| Yan et al | 2015 | Breast cancer | 502 | 504 | 339 | 151 | 12 | 296 | 190 | 18 | |
| Zhang et al | 2014 | Esophageal cancer | 2,098 | 2,150 | 181 | 826 | 1,091 | 78 | 749 | 1,323 | |
| Zhu et al | 2016 | Thyroid cancer | 600 | 600 | 53 | 259 | 288 | 19 | 209 | 372 | |
Abbreviations: Dom, dominant wild type; Hetero, heterozygous genotype; Rec, recessive genotype; SNP, single-nucleotide polymorphism.
Summary of different comparative results of HOTAIR polymorphisms on cancer susceptibility
| SNP | Comparative type | Overall and subgroup | Participants | OR (95% CI) | Effect model | |||
|---|---|---|---|---|---|---|---|---|
| rs7958904 (G/C) | CC vs GG+GC | Overall | 8,816 | 0.82 (0.53, 1.27) | 0.78 | 0.38 | 85 | R |
| CC+GC vs GG | Overall | 8,816 | 0.84 (0.71, 0.99) | 2.06 | 0.04 | 71 | R | |
| GC vs GG+CC | Overall | 7,579 | 0.89 (0.82, 0.98) | 2.52 | 0.01 | 0 | F | |
| CC vs GG | Overall | 4,766 | 0.77 (0.47, 1.24) | 1.08 | 0.28 | 87 | R | |
| C vs G | Overall | 15,158 | 0.86 (0.72, 1.03) | 1.67 | 0.10 | 85 | R | |
| rs4759314 (A/G) | GG vs AA+AG | Overall | 18,235 | 1.37 (0.96, 1.94) | 1.74 | 0.08 | 0 | F |
| Chinese | 17,860 | 1.29 (0.89, 1.87) | 1.34 | 0.18 | 0 | F | ||
| GG+AG vs AA | Overall | 18,235 | 1.11 (0.97, 1.27) | 1.50 | 0.13 | 52 | R | |
| Chinese | 17,860 | 1.13 (0.98, 1.30) | 1.70 | 0.09 | 54 | R | ||
| AG vs AA+GG | Overall | 18,235 | 1.09 (0.95, 1.25) | 1.22 | 0.22 | 51 | R | |
| Chinese | 17,860 | 1.12 (1.02, 1.23) | 2.38 | 0.02 | 47 | F | ||
| GG vs AA | Overall | 16,140 | 1.38 (0.97, 1.96) | 1.78 | 0.08 | 0 | F | |
| Chinese | 15,878 | 1.31 (0.90, 1.90) | 1.42 | 0.15 | 0 | F | ||
| G vs A | Overall | 36,470 | 1.12 (0.98, 1.27) | 1.64 | 0.10 | 54 | R | |
| Chinese | 35,720 | 1.13 (0.98, 1.30) | 1.66 | 0.10 | 58 | R | ||
| rs874945 (G/A) | AA vs GG+GA | Overall | 6,809 | 1.13 (0.88, 1.44) | 0.95 | 0.34 | 0 | F |
| AA+GA vs GG | Overall | 6,809 | 1.10 (0.99, 1.21) | 1.84 | 0.07 | 0 | F | |
| GA vs GG+AA | Overall | 6,809 | 1.08 (0.98, 1.20) | 1.50 | 0.13 | 0 | F | |
| AA vs GG | Overall | 4,768 | 1.16 (0.90, 1.48) | 1.14 | 0.26 | 0 | F | |
| A vs G | Overall | 13,618 | 1.09 (1.00, 1.18) | 1.90 | 0.06 | 0 | F | |
| rs12826786 (C/T) | TT vs CC+CT | Overall | 2,480 | 1.55 (1.19, 2.03) | 3.21 | 0.01 | 40 | F |
| TT+CT vs CC | Overall | 2,480 | 1.23 (1.04, 1.46) | 2.47 | 0.01 | 29 | F | |
| CT vs CC+TT | Overall | 2,480 | 1.04 (0.89, 1.23) | 0.50 | 0.62 | 23 | F | |
| TT vs CC | Overall | 1,431 | 1.67 (1.24, 2.24) | 3.41 | 0.01 | 48 | F | |
| T vs C | Overall | 4,960 | 1.24 (1.09, 1.40) | 3.35 | 0.01 | 35 | F | |
| rs1899663 (G/T) | TT vs GG+GT | Overall | 6,073 | 0.82 (0.60, 1.12) | 1.24 | 0.22 | 0 | F |
| Chinese | 5,696 | 0.72 (0.50, 1.05) | 1.68 | 0.09 | 0 | F | ||
| TT+GT vs GG | Overall | 6,073 | 0.94 (0.84, 1.05) | 1.14 | 0.25 | 0 | F | |
| Chinese | 5,696 | 0.92 (0.82, 1.04) | 1.34 | 0.18 | 0 | F | ||
| GT vs GG+TT | Overall | 6,073 | 0.96 (0.86, 1.08) | 0.70 | 0.49 | 0 | F | |
| Chinese | 5,696 | 0.97 (0.85, 1.10) | 0.50 | 0.62 | 0 | F | ||
| TT vs GG | Overall | 4,358 | 0.81 (0.59, 1.12) | 1.26 | 0.21 | 0 | F | |
| Chinese | 4,184 | 0.71 (0.49, 1.04) | 1.76 | 0.08 | 0 | F | ||
| T vs G | Overall | 12,146 | 0.93 (0.85, 1.03) | 1.38 | 0.17 | 0 | F | |
| Chinese | 11,392 | 0.92 (0.83, 1.02) | 1.66 | 0.10 | 0 | F | ||
| rs920778 (C/T) | TT vs CC+CT | Overall | 11,442 | 1.73 (1.30, 2.30) | 3.79 | 0.01 | 77 | R |
| Chinese | 10,508 | 2.21 (1.72, 2.85) | 6.15 | 0.01 | 61 | R | ||
| TT+CT vs CC | Overall | 11,442 | 1.40 (1.16, 1.70) | 3.45 | 0.01 | 72 | R | |
| Chinese | 10,508 | 1.55 (1.43, 1.69) | 10.22 | 0.01 | 43 | F | ||
| CT vs CC+TT | Overall | 11,442 | 1.10 (0.91, 1.32) | 0.99 | 0.32 | 77 | R | |
| Chinese | 10,508 | 1.20 (0.97, 1.48) | 1.71 | 0.09 | 81 | R | ||
| TT vs CC | Overall | 7,357 | 1.83 (1.25, 2.68) | 3.10 | 0.01 | 79 | R | |
| Chinese | 6,853 | 2.76 (2.31, 3.29) | 11.22 | 0.01 | 0 | F | ||
| T vs C | Overall | 22,884 | 1.37 (1.18, 1.59) | 4.10 | 0.01 | 79 | R | |
| Chinese | 21,016 | 1.56 (1.41, 1.74) | 8.26 | 0.01 | 53 | R |
Abbreviations: F, fixed-effects model; OR, odds ratio; HOTAIR, HOX transcript antisense intergenic RNA; R, random-effects model; SNP, single-nucleotide polymorphism.
Figure 2Representative forest plots.
Notes: (A) TT vs CC+TT of rs12826786 (C/T) polymorphisms. (B) T vs C of rs12826786 (C/T) polymorphisms. (C) TT vs CC+TT in overall group analysis of rs920778 (C/T) polymorphisms. (D) T vs C in overall group analysis of rs920778 (C/T) polymorphisms. *Cervical cancer group.
Abbreviation: df, degrees of freedom.
Figure 3Representative funnel plots of publication bias.
Notes: (A) TT vs CC+TT of rs12826786 (C/T) polymorphisms. (B) T vs C of rs12826786 (C/T) polymorphisms. (C) TT vs CC+TT in overall group analysis of rs920778 (C/T) polymorphisms. (D) T vs C in overall group analysis of rs920778 (C/T) polymorphisms.
Abbreviations: OR, odds ratio; SE, standard error.